Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Regorafenib-nivolumab Combination Therapy for Chemotherapy-naïve Patients With Unresectable or Metastatic Hepatocellular Carcinoma

NCT04310709 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04310709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04310709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Regorafenib-nivolumab Combination Therapy for Chemotherapy-naïve Patients With Unresectable or Metastatic Hepatocellular Carcinoma
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2020
Completion date
November 30, 2022
Enrollment
42 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, hepatoma